Synthesized Depside Molecules Suppress the Progression of Colorectal Cancer by Binding VDAC1/PHB/MMP9 Being at the Crossroads of Stemness, Motility, Apoptosis, and Metabolism

Abstract

Lichen secondary metabolites have shown potential in cancer therapy, but strategies to enhance cancer-specific selectivity are needed. Here, we synthesized depside compounds structurally related to tumidulin (TU) and diffractaic acid (DA) and screened them in vitro, identifying SB4 and SB5 as potent hits. Affinity-based proteomics revealed direct binding to voltage-dependent anion channel 1 (VDAC1), prohibitin (PHB), and matrix metalloproteinase-9 (MMP9), which regulate cancer stemness, motility, metabolism, and apoptosis. SB4 and SB5 exhibited strong cytotoxicity, suppressed cancer stem cell characteristics, inhibited cell motility, impaired mitochondrial respiration, induced reactive oxygen species, and promoted apoptosis. Notably, they reversed cetuximab-induced cancer stemness in colorectal adenocarcinoma-enriched stem cells. In vivo, SB4 and SB5 displayed higher tumor, liver, and intestinal bioavailability than TU and DA following intraperitoneal administration. Pharmacokinetic analyses indicated SB4 had a comparable absorption profile to SB5 with distinct systemic exposures differences. In a CT26/near-infrared fluorescent protein tumor model, SB4 markedly inhibited tumor growth and modulated key markers of stemness, motility, metabolism, and apoptosis in tumor tissues. Collectively, these findings demonstrate that SB4 and SB5 are promising candidates for colorectal cancer therapy by targeting VDAC1/PHB/MMP9.

Keywords

matrix metalloproteinase-9 / probe-based direct binding identification / prohibitin 1 / synthesized depside molecules / voltage-dependent anion-selective channel 1

References

[1] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 209-249.

[2] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer Statistics,” CA: A Cancer Journal for Clinicians 72, no. 1 (2022): 7-33.

[3] C. Jiang, Q. Zhou, K. Yi, Y. Yuan, and X. Xie, “Colorectal Cancer Initiation: Understanding Early-stage Disease for Intervention,” Cancer Letters 589 (2024): 216831.

[4] F. Gila, S. Khoddam, Z. Jamali, et al., “Personalized Medicine in Colorectal Cancer: A Comprehensive Study of Precision Diagnosis and Treatment,” Per Med 22, no. 1 (2025): 59-81.

[5] A. Fadaka, B. Ajiboye, O. Ojo, O. Adewale, I. Olayide, and R. Emuowhochere, “Biology of Glucose Metabolization in Cancer Cells,” Journal of Oncological Sciences 3, no. 2 (2017): 45-51.

[6] J. Yang, C. Shay, N. F. Saba, and Y. Teng, “Cancer Metabolism and Carcinogenesis,” Experimental Hematology & Oncology 13, no. 1 (2024): 1-14.

[7] M. Varlı, E. Y. Lee, S. Y. Park, et al., “An Endolichenic Fungi-Derived Fatty Acid, Cis-10-Nonadecenoic Acid, Suppresses Colorectal Cancer Stemness,” Biomolecules & Therapeutics (Seoul) 33, no. 5 (2025): 842-851. Published online August 6, 2025.

[8] X. Hu, L. Ghisolfi, A. C. Keates, et al., “Induction of Cancer Cell Stemness by Chemotherapy,” Cell Cycle 11, no. 14 (2012): 2691-2698.

[9] L. Liu, L. Yang, W. Yan, et al., “Chemotherapy Induces Breast Cancer Stemness in Association With Dysregulated Monocytosis,” Clinical Cancer Research 24, no. 10 (2018): 2370-2382.

[10] M. Varlı, M. T. Ngo, S. M. Kim, et al., “A Fatty Acid-rich Fraction of an Endolichenic Fungus Phoma sp. suppresses Immune Checkpoint Markers via AhR/ARNT and ESR1,” Heliyon 9, no. 9 (2023): e19185.

[11] B. Ranković, M. Kosanić, T. Stanojković, P. Vasiljević, and N. Manojlović, “Biological Activities of Toninia candida and Usnea Barbata Together With Their Norstictic Acid and Usnic Acid Constituents,” International Journal of Molecular Sciences 13 (2012): 14707-14722.

[12] Z. Solárová, A. Liskova, M. Samec, P. Kubatka, D. Büsselberg, and P. Solár, “Anticancer Potential of Lichens' Secondary Metabolites,” Biomolecules 10, no. 1 (2020): 87.

[13] M. Varlı, S. R. Bhosle, E. Kim, et al., “Usnic Acid Targets 14-3-3 Proteins and Suppresses Cancer Progression by Blocking Substrate Interaction,” JACS Au 4, no. 4 (2024): 1521-1537. Published online 2024.

[14] B. Emsen, A. Aslan, B. Togar, and H. Turkez, “In Vitro Antitumor Activities of the Lichen Compounds Olivetoric, Physodic and Psoromic Acid in Rat Neuron and Glioblastoma Cells,” Pharmaceutical Biology 54, no. 9 (2016): 1748-1762.

[15] B. Cheng, S. Cao, V. Vasquez, et al., “Identification of Anziaic Acid, a Lichen Depside From Hypotrachyna sp., as a New Topoisomerase Poison Inhibitor,” PLoS ONE 8, no. 4 (2013): e60770.

[16] R. Zhou, R. Liu, K. B. Kang, W. Kim, J. S. Hur, and H. Kim, “The Depside Derivative Pericodepside Inhibits Cancer Cell Metastasis and Proliferation by Suppressing Epithelial-Mesenchymal Transition,” ACS Omega 9, no. 6 (2024): 6828-6836.

[17] Y. Yang, S. R. Bhosle, Y. H. Yu, et al., “Tumidulin, a Lichen Secondary Metabolite, Decreases the Stemness Potential of Colorectal Cancer Cells,” Molecules (Basel, Switzerland) 23, no. 11 (2018): 2968.

[18] M. Varlı, S. R. Bhosle, and E. Jo, “Development and Synthesis of Diffractaic Acid Analogs as Potent Inhibitors of Colorectal Cancer Stem Cell Traits,” Scientific Reports 15, no. 1 (2025): 1-20.

[19] A. Magrì, S. Reina, and V. De Pinto, “VDAC1 as Pharmacological Target in Cancer and Neurodegeneration: Focus on Its Role in Apoptosis,” Frontiers in Chemistry 6, no. APR (2018): 108.

[20] M. Owyong, J. Chou, and R. J. E. van den Bijgaart, et al., “MMP9 modulates the Metastatic Cascade and Immune Landscape for Breast Cancer Anti-metastatic Therapy,” Life Science Alliance 2, no. 6 (2019): e201800226.

[21] K. Augoff, A. Hryniewicz-Jankowska, R. Tabola, and K. Stach, “MMP9: A Tough Target for Targeted Therapy for Cancer,” Cancers (Basel) 14, no. 7 (2022): 1847.

[22] L. J. Jiang, S. B. Guo, and Z. Y. Huang, “PHB Promotes Bladder Cancer Cell Epithelial-mesenchymal Transition via the Wnt/β-catenin Signaling Pathway,” Pathology, Research and Practice 247 (2023): 154536.

[23] L. Oyang, J. Li, X. Jiang, et al., “The Function of Prohibitins in Mitochondria and the Clinical Potentials,” Cancer Cell International 22, no. 1 (2022): 1-10.

[24] F. Liu, Y. Zhang, Z. Guo, and A. J. Ren, “The Role of Prohibitin-2 in Diseases,” Frontiers in Bioscience-Landmark 28, no. 9 (2023): 211.

[25] V. Shoshan-Barmatz, E. N. Maldonado, and Y. Krelin, “VDAC1 at the Crossroads of Cell Metabolism, Apoptosis and Cell Stress,” Cell Stress 1, no. 1 (2017): 11.

[26] M. Córdova-Delgado, S. Fuentes-Retamal, C. Palominos, et al., “Fri-1 Is an Anti-cancer Isoquinolinequinone That Inhibits the Mitochondrial Bioenergetics and Blocks Metabolic Shifts by Redox Disruption in Breast Cancer Cells,” Antioxidants 10, no. 10 (2021): 1618.

[27] S. Fulda, L. Galluzzi, and G. Kroemer, “Targeting Mitochondria for Cancer Therapy,” Nature Reviews Drug Discovery 9, no. 6 (2010): 447-464.

[28] A. P. Moreno-Londoño and M. Robles-Flores, “Functional Roles of CD133: More Than Stemness Associated Factor Regulated by the Microenvironment,” Stem Cell Reviews and Reports 20, no. 1 (2024): 25-51.

[29] S. Pulat, J. A. G. Paguiri, C. D. B. Gamage, et al., “Lobaric Acid Suppresses the Stemness Potential of Colorectal Cancer Cells Through mTOR/AKT,” Biofactors 51, no. 1 (2025): e70002.

[30] J. Lauterwasser, F. Fimm-Todt, A. Oelgeklaus, et al., “Hexokinases Inhibit Death Receptor-dependent Apoptosis on the Mitochondria,” PNAS 118, no. 33 (2021): e2021175118.

[31] S. Tanaka, W. Kobayashi, M. Haraguchi, K. Ishihata, N. Nakamura, and M. Ozawa, “Snail1 expression in human Colon Cancer DLD-1 Cells Confers Invasive Properties Without N-cadherin expression,” Biochemistry and Biophysics Reports 8 (2016): 120-126.

[32] S. Ishikawa, N. Nishida, S. Fujino, et al., “Comprehensive Profiling of Novel Epithelial-mesenchymal Transition Mediators and Their Clinical Significance in Colorectal Cancer,” Scientific Reports 11, no. 1 (2021): 1-16.

[33] Z. Sun, Q. Dang, Z. Liu, et al., “LINC01272/miR-876/ITGB2 Axis Facilitates the Metastasis of Colorectal Cancer via Epithelial-mesenchymal Transition,” Journal of Cancer 12, no. 13 (2021): 3909-3919.

[34] M. H. Yazdi, M. A. Faramarzi, S. Nikfar, and M. Abdollahi, “A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer,” Avicenna Journal of Medical Biotechnology 7, no. 4 (2015): 134.

[35] C. S. Karapetis, S. Khambata-Ford, D. J. Jonker, et al., “K-ras Mutations and Benefit From Cetuximab in Advanced Colorectal Cancer,” New England Journal of Medicine 359, no. 17 (2008): 1757-1765.

[36] G. Ulus, “Antiangiogenic Properties of Lichen Secondary Metabolites,” Phytotherapy Research 35, no. 6 (2021): 3046-3058.

[37] A. T. Koparal, G. Ulus, M. Zeytinoǧlu, T. Tay, and A. Ö. Türk, “Angiogenesis Inhibition by a Lichen Compound Olivetoric Acid,” Phytotherapy Research 24, no. 5 (2010): 754-758.

[38] H. Stoeckli-Evans and D. Blaser, “Structure of the Methyl Esters of Barbatic and Evernic Acids: Natural Para-depsides,” Acta Crystallographica Section C Crystal Structure Communications 47, no. 12 (1991): 2620-2624.

[39] Ş. Günaydın, E. K. Sulukoğlu, Ş. N. Kalın, A. Altay, and H. Budak, “Diffractaic Acid Exhibits Thioredoxin Reductase 1 Inhibition in Lung Cancer A549 Cells,” Journal of Applied Toxicology 43, no. 11 (2023): 1676-1685.

[40] A. Rasola, M. Sciacovelli, B. Pantic, and P. Bernardi, “Signal Transduction to the Permeability Transition Pore,” FEBS Letters 584, no. 10 (2010): 1989-1996.

[41] M. Bachmann, R. Costa, R. Peruzzo, E. Prosdocimi, V. Checchetto, and L. Leanza, “Targeting Mitochondrial Ion Channels to Fight Cancer,” International Journal of Molecular Sciences 19, no. 7 (2018): 2060.

[42] M. Roy, S. Nandy, E. Marchesan, et al. Efficient Prohibitin 2 exposure during mitophagy depends on Voltage-dependent anion-selective channel protein 1. bioRxiv. Published online October 12, 2023: 2023.10.10.561633.

[43] F. Thuaud, N. Ribeiro, C. G. Nebigil, and L. Désaubry, “Prohibitin Ligands in Cell Death and Survival: Mode of Action and Therapeutic Potential,” Chemistry & Biology 20, no. 3 (2013): 316-331.

[44] S. Koushyar, W. G. Jiang, and D. A. Dart, “Unveiling the Potential of Prohibitin in Cancer,” Cancer Letters 369, no. 2 (2015): 316-322.

[45] C. H. Fang, Y. T. Lin, C. M. Liang, and S. M. Liang, “A Novel c-Kit/Phospho-prohibitin Axis Enhances Ovarian Cancer Stemness and Chemoresistance via Notch3-PBX1 and β-catenin-ABCG2 Signaling,” Journal of Biomedical Science 27, no. 1 (2020): 42.

[46] C. F. Chiu, M. Y. Ho, J. M. Peng, et al., “Raf Activation by Ras and Promotion of Cellular Metastasis Require Phosphorylation of Prohibitin in the Raft Domain of the Plasma Membrane,” Oncogene 32, no. 6 (2012): 777-787.

[47] S. C. Gamble, M. Odontiadis, J. Waxman, et al., “Androgens Target Prohibitin to Regulate Proliferation of Prostate Cancer Cells,” Oncogene 23, no. 17 (2004): 2996-3004.

[48] Y. Cao, H. Liang, F. Zhang, et al., “Prohibitin Overexpression Predicts Poor Prognosis and Promotes Cell Proliferation and Invasion Through ERK Pathway Activation in Gallbladder Cancer,” Journal of Experimental and Clinical Cancer Research 35, no. 1 (2016): 1-11.

[49] K. Kessenbrock, C. Y. Wang, and Z. Werb, “Matrix Metalloproteinases in Stem Cell Regulation and Cancer,” Matrix Biology 44-46 (2015): 184-190.

[50] H. Huang, “Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances,” Sensors 18, no. 10 (2018): 3249.

[51] F. Zinghirino, X. G. Pappalardo, A. Messina, G. Nicosia, V. De Pinto, and F. Guarino, “VDAC Genes Expression and Regulation in Mammals,” Frontiers in Physiology 12 (2021): 708695.

[52] A. Qi, L. Lamont, E. Liu, S. D. Murray, X. Meng, and S. Yang, “Essential Protein PHB2 and Its Regulatory Mechanisms in Cancer,” Cells 12, no. 8 (2023): 1211.

[53] Z. Zhao, X. Song, Y. Wang, et al., “E3 ubiquitin Ligase TRIM31 Alleviates Dopaminergic Neurodegeneration by Promoting Proteasomal Degradation of VDAC1 in Parkinson's Disease Model,” Cell Death & Differentiation 31, no. 11 (2024): 1410-1421.

[54] S. J. Ham, D. Lee, H. Yoo, K. Jun, H. Shin, and J. Chung, “Decision Between Mitophagy and Apoptosis by Parkin via VDAC1 Ubiquitination,” PNAS 117, no. 8 (2020): 4281-4291.

[55] J. Zhao, J. Dai, N. Zhou, et al., “UBE2C regulating the Lung Carcinoma Progression via Inhibiting Ubiquitin-proteasomal Degradation to Increase MMP9 Protein Stability,” Genes Genomics 47, no. 6 (2025): 651-662.

[56] K. Zybura-Broda, M. Wolder-Gontarek, M. Ambrozek-Latecka, et al., “HuR (Elavl1) and HuB (Elavl2) Stabilize Matrix Metalloproteinase-9 mRNA During Seizure-induced Mmp-9 Expression in Neurons,” Frontiers in Neuroscience 12, no. APR (2018): 348594.

[57] K. Dey and S. De, “microRNAs-Mediated Regulation of Voltage Gated Anion Channel 1, a Major Player in ROS Generation and Cancer Progression,” Handbook of Oxidative Stress in Cancer: Therapeutic Aspects (2022): 1-8. Published online.

[58] Z. Koveitypour, F. Panahi, M. Vakilian, et al., “Signaling Pathways Involved in Colorectal Cancer Progression,” Cell & Bioscience 9, no. 1 (2019): 97.

[59] C. Karamboulas and L. Ailles, “Developmental Signaling Pathways in Cancer Stem Cells of Solid Tumors,” Biochimica Et Biophysica Acta (BBA)-General Subjects 1830, no. 2 (2013): 2481-2495.

[60] L. Du, Q. Cheng, H. Zheng, J. Liu, L. Liu, and Q. Chen, “Targeting Stemness of Cancer Stem Cells to Fight Colorectal Cancers,” Seminars in Cancer Biology 82 (2022): 150-161.

[61] C. Li, X. Yang, Y. Cheng, and J. Wang, “LGR5, a Prognostic Stem Cell Target, Promotes Endometrial Cancer Proliferation Through Autophagy Activation,” Translational Oncology 40 (2024): 101853.

[62] M. Niyaz, M. S. Khan, and S. Mudassar, “Hedgehog Signaling: An Achilles' Heel in Cancer,” Translational Oncology 12, no. 10 (2019): 1334.

[63] Z. Yao, L. Han, Y. Chen, et al., “Hedgehog Signalling in the Tumourigenesis and Metastasis of Osteosarcoma, and Its Potential Value in the Clinical Therapy of Osteosarcoma,” Cell Death & Disease 9, no. 6 (2018): 1-12.

[64] S. Y. Mohamed, R. M. Kaf, M. M. Ahmed, A. Elwan, H. R. Ashour, and A. Ibrahim, “The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma,” Journal of Gastrointestinal Cancer 50, no. 4 (2019): 824-837.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.